# Script CJC-1295 — References

> Primary sources cited across this site: peer-reviewed peptide pharmacology and Phase 1 human research, the ClinicalTrials.gov record for NCT00267527, FDA briefing materials and 503A documents, and the WADA Prohibited List.

Every primary source cited on this site, with DOI or FDA docket identifier, and a link to the original record. Filterable by source type.

## Primary sources

The references below are the complete primary-source list for this site. Inline numerals on other pages — [1], [2], and so on — map to the numbered entries here. Sources span peer-reviewed peptide pharmacology, the ClinicalTrials.gov record, FDA briefing materials and 503A guidance documents, the World Anti-Doping Code Prohibited List, the FDA Drugs@FDA database, and one HHS public statement.

Where multiple page-citations rely on the same primary source (for example, the Teichman 2006 Phase 1 paper appears in /index, /research, /dosage, and /faq), the source is listed once and referenced repeatedly. The full citation list is reproduced in `llms-full.txt` for machine-readable consumption.

This site is an independent editorial reading of publicly available research — not affiliated with any vendor, clinic, or prescriber.

## References

[1] Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[2] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[3] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults [PK substudy: mean plasma half-life 5.8-8.1 days]. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[6] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[7] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010;2(11-12):647-650. https://pubmed.ncbi.nlm.nih.gov/21204297/
[8] ConjuChem Biotechnologies Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity (NCT00267527). ClinicalTrials.gov, 2006. https://clinicaltrials.gov/study/NCT00267527
[9] Jetté L, Léger R, Thibaudeau K, et al. [Mechanistic note: four amino acid substitutions in modified GRF(1-29) extend in-vivo half-life from ~7 minutes (native GHRH) to ~30 minutes.] Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[10] Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fußhöller G, Görgens C, Geyer H, Thevis M. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Journal of Mass Spectrometry. 2024;59(2):e4996. https://pubmed.ncbi.nlm.nih.gov/38197510/
[11] Steiger A, Guldner J, Hemmeter U, et al. Growth hormone-releasing hormone (GHRH) and sleep regulation. Psychoneuroendocrinology. 1992;17(2-3):143-156. https://pubmed.ncbi.nlm.nih.gov/1438644/
[12] Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Combined administration of GHRH and GHRP-6 acts in synergy on growth hormone (GH) release in humans. Journal of Clinical Endocrinology and Metabolism. 1990;70(4):975-982. https://pubmed.ncbi.nlm.nih.gov/2107173/
[13] World Anti-Doping Agency. World Anti-Doping Code International Standard — The 2025 Prohibited List. WADA, 2025. [Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics.] https://www.wada-ama.org/en/prohibited-list
[14] U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs (search: 'CJC-1295' returns no approved products). FDA Drug Database, 2025. https://www.accessdata.fda.gov/scripts/cder/daf/
[15] U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee — CJC-1295 Briefing Materials (Docket FDA-2024-N-4777). FDA Briefing Materials, 2024. https://www.fda.gov/media/182088/download
[16] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (FDA listing updates — removal of CJC-1295 from Category 2 effective September 27, 2024). FDA.gov, 2024. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[17] U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee Meeting — Briefing Materials on GH Secretagogue Peptides (Docket FDA-2024-N-4777). FDA Briefing Materials, 2024. https://www.fda.gov/media/183819/download
[18] U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (Final Guidance for Industry, January 2025). FDA Guidance for Industry, 2025. https://www.fda.gov/media/174456/download
[19] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25027139/
[20] U.S. Congress / U.S. Food and Drug Administration. Section 503A of the Federal Food, Drug, and Cosmetic Act — Pharmacy Compounding of Human Drug Products. 21 U.S.C. § 353a, 1997. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
[21] Van Hout MC, Hearne E. Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Substance Use & Misuse. 2016;51(1):73-84. https://pubmed.ncbi.nlm.nih.gov/26771670/
[22] U.S. Department of Health and Human Services. HHS Secretary Statement on Peptide Reclassification (Joe Rogan Experience #2461, February 27, 2026). HHS Public Statement, 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[23] Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. https://pubmed.ncbi.nlm.nih.gov/15110491/
[24] GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron [mechanism study]. J Clin Endocrinol Metab. 2002. https://pubmed.ncbi.nlm.nih.gov/11932310/
[25] Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. https://pubmed.ncbi.nlm.nih.gov/20943777/
[26] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[27] Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions [review]. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/

---

An independent editorial reading of publicly available research — not a clinic, not a prescriber, not a vendor.